Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.
- During a recent TechMediaWire Podcast appearance, Justin Hanka outlined MindBio Therapeutics’ progress in developing advanced AI-driven voice analysis technology for drug and alcohol intoxication detection.
- MindBio Therapeutics Corp. says its prediction models are trained using more than 50 million data points collected through years of clinical and behavioral research.
- The company’s initial commercial strategy focuses on workplace safety sectors including mining, aviation, and construction, where impairment-related incidents carry significant operational and regulatory risks.
- Hanka said during the interview that the company’s voice-analysis platform can detect not only alcohol intoxication but also drugs affecting the central nervous system, including cannabis, cocaine, opioids, and psychedelics.
- Management expects live workplace testing deployments to begin later in the second quarter of 2026 as the company transitions from development toward commercial implementation.
- MindBio views its technology as part of a broader AI-driven diagnostics technology capable of supporting future health and wellness applications beyond intoxication monitoring.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company commercializing AI-driven voice technology for drug and alcohol intoxication detection, used a recent appearance on the TechMediaWire Podcast to outline how the company plans to commercialize its technology, starting with testing plans as of Q2 this year (https://ibn.fm/HLMKz). During the discussion with podcast host Stuart Smith, MindBio Founder and Chief Executive Officer Justin Hanka described the company’s work using speech analytics and machine learning to identify physiological indicators associated with intoxication through non-invasive voice analysis (https://ibn.fm/BUKfp).
According to Hanka, MindBio has spent several years conducting drug and alcohol research while collecting extensive speech and voice datasets through clinical studies and related programs. As AI and machine-learning systems have improved, the company believes it has developed models capable of identifying intoxication by analyzing vocal patterns, cadence and speech characteristics. The company says its prediction models are built using more than 50 million data points and are designed to evaluate changes in speech linked to alcohol and drug use.
A central theme of the podcast discussion was how MindBio’s technology differs from traditional intoxication testing methods. Hanka contrasted the company’s voice-based approach with conventional testing systems that rely on biological samples such as breath, saliva, urine, blood or hair analysis.
MindBio’s platform instead seeks to provide a scalable, non-invasive screening method that can operate in workplace and public environments without interrupting operations or requiring physical sample collection.
During the interview, Hanka emphasized that the technology’s commercial potential extends well beyond alcohol detection. He said the company’s AI models can now identify indicators associated with multiple categories of drugs that affect the central nervous system. Those categories include cannabis, cocaine, opioids and psychedelic substances such as psilocybin and lysergic acid diethylamide, commonly known as LSD.
Management characterized those developments as an important expansion of the company’s capabilities because large-scale detection of non-alcohol intoxication remains operationally difficult in many workplace environments.
The company’s initial commercial focus is workplace health and safety, particularly in sectors with elevated operational risk and mandatory testing requirements. During the podcast discussion, Hanka pointed specifically to the mining industry as an early entry market. He described mining operations as environments where regulators, operators and labor organizations all have incentives to reduce impairment-related incidents because workplace shutdowns can create substantial financial consequences.
According to Hanka, many mining operations currently rely on random testing protocols because continuously screening thousands of workers entering industrial sites is difficult using conventional methods. MindBio believes its voice-analysis platform could substantially increase testing frequency at entry gates or throughout operational sites.
The company also discussed opportunities in aviation, construction, and law enforcement environments, where scalable intoxication screening can improve safety monitoring.
Another topic raised during the interview was the adaptability of the company’s technology across languages and regions. Hanka said MindBio has trained its models using multilingual voice samples and varying accents, including English- and Spanish-language datasets relevant to South American markets. The company has already begun discussions tied to potential mining-sector deployments in Chile and other South American jurisdictions.
MindBio is currently building enterprise deployment systems that combine proprietary software with Edge-AI hardware kiosks capable of rapidly analyzing speech inputs. Management says intoxication assessments can occur in less than three seconds.
Hanka also used the podcast interview to outline several operational objectives for 2026. He said the company has recently completed key funding milestones, raised approximately $2.5 million for development activities and continued refining its prediction models and deployment systems.
Most importantly, management expects the company’s technology to enter live workplace testing later in the second quarter of 2026. Hanka described that rollout as a significant milestone because it represents the transition from research and engineering toward practical commercial implementation.
The interview also highlighted the company’s broader ambitions beyond workplace intoxication detection. Hanka suggested that MindBio increasingly sees itself evolving into a broader diagnostics business centered around AI-driven voice analytics. The underlying concept is that speech may function as a biomarker for a range of physiological and neurological conditions because vocal characteristics can reflect changes occurring inside the body.
For more information, visit the company’s website at www.MindBioTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
About QualityStocks
QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer
QualityStocks
Austin, Texas
www.QualityStocks.com
512.354.7000 Office
Editor@QualityStocks.com
QualityStocks is powered by IBN
